Calreticulin gene mutations in the myeloproliferative neoplasms: Dameshek's other “myelostimulatory” factor

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations

(2014) Chao Sun et al.   LEUKEMIA & LYMPHOMA

JAK Inhibitor in CALR-Mutant Myelofibrosis

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders

(2010) B. L. Stein et al.   HAEMATOLOGICA